Aurora Cannabis Announces Fiscal 2027 First Quarter Results
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) reported fiscal 2027 Q1 results for the quarter ended June 30, 2026. Net revenue fell to $67.6M from $74.1M, while international medical cannabis net revenue rose 17% to $43.3M. Net loss from continuing operations was $4.0M. The company said it has $149.1M cash and no debt and that Safari Flower received EU-GMP certification.
How this was made
The 30-second read
Why it matters
The key tradable elements are the reported Q1 financial datapoints (revenue, gross margin, adjusted EBITDA, free cash flow) and the stated expectation for sequential improvement in Q2, alongside the operational catalyst of Safari’s EU-GMP certification.
Market read
This is a company-specific earnings release with fresh quarterly results and a near-term sequential improvement expectation, plus a concrete operational milestone tied to EU-GMP supply capacity.
What to watch
The article emphasizes sequential improvement in Q2 but provides no new quantitative guidance range; traders may need to watch whether EU-GMP capacity investments translate into margin recovery rather than only revenue growth.
Background
Aurora Cannabis is shifting resources toward global medical cannabis and has exited low-margin Canadian consumer and plant propagation businesses, while expanding EU-GMP manufacturing capacity via Safari Flower Company.
Ticker impact
Aurora reported fiscal Q1 2027 results, including $67.6M net revenue, international revenue growth, and a sequential Q2 revenue and Adjusted EBITDA improvement outlook.
Near-term trading likely hinges on whether investors focus on the Canada reimbursement-driven margin compression versus the international growth and EU-GMP capacity catalyst.
The release contains fresh quarterly financials and a forward sequential improvement expectation for Q2, but it also highlights a material YoY decline in adjusted EBITDA and gross margin before fair value adjustments.
Market effects
Highlights ongoing EU-GMP capacity buildout as a competitive lever for Canadian medical cannabis producers targeting higher-margin international markets.
Canada reimbursement policy changes are shown to directly pressure Canadian medical cannabis revenue and margins, while Germany demand supports international growth.
EU-GMP certification and manufacturing capacity expansion can influence supply expectations for medical cannabis across EU markets.
Counterpoint
Investors may discount the international growth narrative if adjusted gross margin on medical cannabis continues to fall due to reimbursement-driven economics, limiting earnings quality.
Key entities
- companyAurora Cannabis Inc.
Reported fiscal Q1 2027 results and reiterated full-year 2027 outlook, citing international growth and EU-GMP capacity expansion.
- companySafari Flower Company
Safari received three-year EU-GMP certification for its Ontario facility, supporting Aurora’s EU-GMP manufacturing capacity plans.
- companyBevo Agtech Inc.
Aurora divested its 50.1% ownership interest in Bevo, which is excluded from comparative figures as a discontinued operation.
